

1. Sales January to March 2009 and 2008

January – March	2009	2008	% change	
	CHF m	CHF m	In CHF	In local currencies
Pharmaceuticals Division	9,216	8,568	+8	+8
Europe/Rest of World	4,491	4,571	-2	+8
US	3,586	3,326	+8	+1
Japan	1,139	671	+70	+40
Diagnostics Division	2,361	2,287	+3	+8
Roche Group	11,577	10,855	+7	+8

2. Quarterly local sales growth by Division in 2008 and 2009

	Q2 2008 vs. Q2 2007	Q3 2008 vs. Q3 2007	Q4 2008 vs. Q4 2007	Q1 2009 vs. Q1 2008
Pharmaceuticals Division	+5	+8	+5	+8
Europe/Rest of World	+9	+7	+10	+8
US	0	+12	0	+1
Japan	+2	-1	+5	+40
Diagnostics Division	+13	+11	+9	+8
Roche Group	+7	+9	+6	+8

3. Quarterly sales by Division in 2008 and 2009

CHF millions	Q1 2008	Q2 2008	Q3 2008	Q4 2008	Q1 2009
Pharmaceuticals Division	8,568	8,689	8,936	9,768	9,216
Europe/Rest of World	4,571	4,661	4,637	4,727	4,491
US	3,326	3,247	3,517	3,939	3,586
Japan	671	781	782	1,102	1,139
Diagnostics Division	2,287	2,460	2,365	2,544	2,361
Roche Group	10,855	11,149	11,301	12,312	11,577

4. Top 20 Pharmaceuticals Division product sales and local growth¹ in YTD March 2009: US, Japan and Europe/Rest of World

	Total		US		Japan		Europe/RoW	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Avastin	1,485	30%	810	18%	82	147%	593	39%
MabThera/Rituxan	1,481	6%	769	6%	52	2%	660	6%
Herceptin	1,307	11%	390	0%	81	62%	836	13%
CellCept	517	7%	256	11%	11	15%	250	3%
Tamiflu	401	38%	15	-94%	250	1207%	136	487%
Pegasys	393	9%	101	17%	31	36%	261	5%
NeoRecormon/Epogin	378	-13%	-	-	115	-8%	263	-15%
Tarceva	320	13%	128	0%	15	51%	177	20%
Xeloda	296	8%	106	11%	15	53%	175	4%
Lucentis	279	21%	279	21%	-	-	-	-
Bonviva/Boniva	249	3%	137	-17%	-	-	112	40%
Xolair	152	13%	152	13%	-	-	-	-
Valcyte/Cymevene	131	7%	60	3%	-	-	71	11%
Activase/TNKase	126	45%	114	49%	-	-	12	19%
Pulmozyme	120	3%	75	14%	-	-	45	-9%
Nutropin	104	1%	101	1%	-	-	3	-12%
Xenical	103	-14%	8	-43%	-	-	95	-11%
Neutrogen	90	-22%	-	-	90	-22%	-	-
Rocephin	77	-15%	0	-97%	15	-3%	62	-13%
Madopar	68	0%	-	-	5	7%	63	0%

¹ versus YTD March 2008

5. Top 20 Pharmaceuticals Division quarterly local product sales growth in 2008 and 2009

	Q2 2008 vs. Q2 2007	Q3 2008 vs. Q3 2007	Q4 2008 vs. Q4 2007	Q1 2009 vs. Q1 2008
Avastin	38%	37%	36%	30%
MabThera/Rituxan	16%	15%	16%	6%
Herceptin	12%	14%	12%	11%
CellCept	16%	14%	11%	7%
Tamiflu	-86%	-56%	-65%	38%
Pegasys	10%	12%	5%	9%
NeoRecormon/Epogin	-14%	-15%	-8%	-13%
Tarceva	27%	18%	19%	13%
Xeloda	14%	14%	12%	8%
Lucentis	2%	15%	19%	21%
Bonviva/Boniva	47%	26%	23%	3%
Xolair	7%	12%	13%	13%
Valcyte/Cymevene	10%	13%	9%	7%
Activase/TNKase	-11%	-2%	13%	45%
Pulmozyme	11%	6%	14%	3%
Nutropin	-5%	1%	-1%	1%
Xenical	-21%	-9%	-11%	-14%
Neutrogen	1%	0%	-13%	-22%
Rocephin	-13%	-16%	-6%	-15%
Madopar	9%	4%	3%	0%

6. Pharmaceuticals Division quarterly local product sales growth US in 2008 and 2009

	Q2 2008 vs. Q2 2007	Q3 2008 vs. Q3 2007	Q4 2008 vs. Q4 2007	Q1 2009 vs. Q1 2008
Avastin	15%	18%	21%	18%
MabThera/Rituxan	13%	14%	15%	6%
Herceptin	3%	15%	3%	0%
CellCept	15%	20%	12%	11%
Tamiflu	-87%	6%	-83%	-94%
Pegasys	5%	45%	9%	17%
NeoRecormon/Epogin	-	-	-	-
Tarceva	17%	9%	5%	0%
Xeloda	5%	9%	8%	11%
Lucentis	2%	15%	19%	21%
Bonviva/Boniva	39%	16%	12%	-17%
Xolair	7%	12%	13%	13%
Valcyte/Cymevene	5%	7%	5%	3%
Activase/TNKase	-12%	-2%	13%	49%
Pulmozyme	14%	13%	24%	14%
Nutropin	-4%	1%	-1%	1%
Xenical	-46%	-33%	-48%	-43%
Neutrogen	-	-	-	-
Rocephin	-85%	-	-89%	-97%
Madopar	-	-	-	-

7. Pharmaceuticals Division quarterly local product sales growth Japan in 2008 and 2009

	Q2 2008 vs. Q2 2007	Q3 2008 vs. Q3 2007	Q4 2008 vs. Q4 2007	Q1 2009 vs. Q1 2008
Avastin	1567%	442%	236%	147%
MabThera/Rituxan	11%	8%	9%	2%
Herceptin	29%	69%	73%	62%
CellCept	21%	15%	10%	15%
Tamiflu	-78%	-98%	-2%	1207%
Pegasys	53%	49%	39%	36%
NeoRecormon/Epogin	-29%	-9%	-16%	-8%
Tarceva	-	-	699%	51%
Xeloda	73%	88%	81%	53%
Lucentis	-	-	-	-
Bonviva/Boniva	-	-	-	-
Xolair	-	-	-	-
Valcyte/Cymevene	-	-	-	-
Activase/TNKase	-	-	-	-
Pulmozyme	-	-	-	-
Nutropin	-	-	-	-
Xenical	-	-	-	-
Neutrogen	1%	0%	-13%	-22%
Rocephin	-2%	-1%	5%	-3%
Madopar	5%	6%	0%	7%

8. Pharmaceuticals Division quarterly local product sales growth Europe/Rest of World in 2008 and 2009

	Q2 2008 vs. Q2 2007	Q3 2008 vs. Q3 2007	Q4 2008 vs. Q4 2007	Q1 2009 vs. Q1 2008
Avastin	78%	67%	52%	39%
MabThera/Rituxan	21%	17%	18%	6%
Herceptin	15%	11%	13%	13%
CellCept	16%	9%	9%	3%
Tamiflu	-83%	-93%	6%	487%
Pegasys	9%	1%	1%	5%
NeoRecormon/Epogin	-7%	-17%	-4%	-15%
Tarceva	28%	17%	24%	20%
Xeloda	18%	14%	12%	4%
Lucentis	-	-	-	-
Bonviva/Boniva	61%	45%	47%	40%
Xolair	-	-	-	-
Valcyte/Cymevene	16%	19%	14%	11%
Activase/TNKase	1%	1%	11%	19%
Pulmozyme	8%	-3%	2%	-9%
Nutropin	-12%	-10%	-2%	-12%
Xenical	-17%	-6%	-7%	-11%
Neutrogin	-	-	-	-
Rocephin	-9%	-13%	-6%	-13%
Madopar	9%	4%	4%	0%

9. Top 20 Pharmaceuticals Division quarterly product sales in 2008 and 2009

CHF millions	Q1 2008	Q2 2008	Q3 2008	Q4 2008	Q1 2009
Avastin	1,131	1,220	1,351	1,505	1,485
MabThera/Rituxan	1,407	1,460	1,472	1,584	1,481
Herceptin	1,225	1,249	1,295	1,323	1,307
CellCept	487	523	513	576	517
Tamiflu	278	49	101	181	401
Pegasys	369	416	405	445	393
NeoRecormon/Epogin	442	450	427	455	378
Tarceva	286	301	298	330	320
Xeloda	281	292	307	331	296
Lucentis	215	225	246	274	279
Bonviva/Boniva	241	266	268	333	249
Xolair	125	134	145	156	152
Valcyte/Cymevene	125	136	143	149	131
Activase/TNKase	83	81	81	97	126
Pulmozyme	117	120	120	139	120
Nutropin	97	98	106	112	104
Xenical	136	128	126	112	103
Neutrogen	95	97	98	114	90
Rocephin	91	85	76	92	77
Madopar	74	80	77	80	68

10. Pharmaceuticals Division quarterly product sales in US in 2008 and 2009

CHF millions	Q1 2008	Q2 2008	Q3 2008	Q4 2008	Q1 2009
Avastin	642	671	754	841	810
MabThera/Rituxan	675	706	732	817	769
Herceptin	363	349	394	390	390
CellCept	215	243	247	321	256
Tamiflu	234	30	96	70	15
Pegasys	81	95	99	120	101
NeoRecormon/Epogin	-	-	-	-	-
Tarceva	119	123	117	136	128
Xeloda	89	97	111	131	106
Lucentis	215	225	246	274	279
Bonviva/Boniva	153	159	155	208	137
Xolair	125	134	145	156	152
Valcyte/Cymevene	54	62	66	76	60
Activase/TNKase	71	71	70	86	114
Pulmozyme	61	65	69	83	75
Nutropin	94	94	104	109	101
Xenical	14	12	9	8	8
Neutrogen	-	-	-	-	-
Rocephin	3	1	0	1	0
Madopar	-	-	-	-	-

11. Pharmaceuticals Division quarterly product sales in Japan in 2008 and 2009

CHF millions	Q1 2008	Q2 2008	Q3 2008	Q4 2008	Q1 2009
Avastin	28	43	57	82	82
MabThera/Rituxan	43	52	51	68	52
Herceptin	42	56	64	87	81
CellCept	8	11	9	13	11
Tamiflu	16	0	1	71	250
Pegasys	19	22	26	35	31
NeoRecormon/Epogin	103	114	111	142	115
Tarceva	8	12	11	16	15
Xeloda	8	12	13	17	15
Lucentis	-	-	-	-	-
Bonviva/Boniva	-	-	-	-	-
Xolair	-	-	-	-	-
Valcyte/Cymevene	-	-	-	-	-
Activase/TNKase	-	-	-	-	-
Pulmozyme	-	-	-	-	-
Nutropin	-	-	-	-	-
Xenical	-	-	-	-	-
Neutrogen	95	97	98	114	90
Rocephin	13	15	14	19	15
Madopar	4	5	5	6	5

12. Pharmaceuticals Division quarterly product sales in Europe/Rest of World in 2008 and 2009

CHF millions	Q1 2008	Q2 2008	Q3 2008	Q4 2008	Q1 2009
Avastin	461	506	540	582	593
MabThera/Rituxan	689	702	689	699	660
Herceptin	820	844	837	846	836
CellCept	264	269	257	242	250
Tamiflu	28	19	4	40	136
Pegasys	269	299	280	290	261
NeoRecormon/Epogin	339	336	316	313	263
Tarceva	159	166	170	178	177
Xeloda	184	183	183	183	175
Lucentis	-	-	-	-	-
Bonviva/Boniva	88	107	113	125	112
Xolair	-	-	-	-	-
Valcyte/Cymevene	71	74	77	73	71
Activase/TNKase	12	10	11	11	12
Pulmozyme	56	55	51	56	45
Nutropin	3	4	2	3	3
Xenical	122	116	117	104	95
Neutrogen	-	-	-	-	-
Rocephin	75	69	62	72	62
Madopar	70	75	72	74	63